Compositions and methods for retargeting virus constructs
    1.
    发明授权
    Compositions and methods for retargeting virus constructs 有权
    用于重定向病毒构建体的组合和方法

    公开(公告)号:US09458473B2

    公开(公告)日:2016-10-04

    申请号:US13807359

    申请日:2011-06-29

    摘要: The present invention relates to the field of viral gene therapy. More specifically, the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP (SEQ ID NO:45), wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP (SEQ ID NO:10) inserted into the HI-loop of adenovirus fiber protein. In yet another embodiment, the present invention provides a method for optimizing adenoviral infection of target cells comprising the steps of (a) generating a peptide-display adenovirus library, wherein the displayed peptide is a peptide that specifically binds an antigen expressed on the surface of a target cell, and wherein the displayed peptide is flanked by random peptide sequences; and (b) screening the peptide-display adenovirus library against the target cells.

    摘要翻译: 本发明涉及病毒基因治疗领域。 更具体地,本发明提供了用于重新靶向病毒构建体的组合物和方法。 在一个实施方案中,本发明提供了包含编码肽序列MAE-X-PDP(SEQ ID NO:45)的核酸的腺病毒构建体,其中X是抗原靶向肽。 在更具体的实施方案中,腺病毒构建体包含编码插入到腺病毒纤维蛋白的HI环中的肽序列MAEWQPDTAHHWALTLPDP(SEQ ID NO:10)的核酸序列。 在另一个实施方案中,本发明提供了用于优化靶细胞的腺病毒感染的方法,包括以下步骤:(a)产生肽显示腺病毒文库,其中所显示的肽是特异性结合表达在 靶细胞,并且其中所显示的肽侧翼为随机肽序列; 和(b)筛选针对靶细胞的肽显示腺病毒文库。

    COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING CIRCULATING TUMOR CELLS (CTCs)
    2.
    发明申请
    COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING CIRCULATING TUMOR CELLS (CTCs) 审中-公开
    用于检测和定量循环肿瘤细胞(CTC)的组合物和方法

    公开(公告)号:US20140017668A1

    公开(公告)日:2014-01-16

    申请号:US13807366

    申请日:2011-06-30

    IPC分类号: C12Q1/68 C12N15/86

    摘要: The present invention relates to the field of virology. More specifically, the present invention relates to the use of viral constructs to detect and quantify circulating tumor cells. In one embodiment, the present invention provides an adenovirus construct comprising (a) a cell type specific promoter that drives adenoviral replication; and (b) at least one reporter gene incorporated into the viral Major Late Transcriptional Unit. In another embodiment, an adenovirus construct comprises (a) prostate selective pro-basin promoter operably linked to the El gene; and (b) prostate specific antigen enhancer operably linked to the probasin promoter.

    摘要翻译: 本发明涉及病毒学领域。 更具体地,本发明涉及病毒构建体检测和定量循环肿瘤细胞的用途。 在一个实施方案中,本发明提供了一种腺病毒构建体,其包含(a)驱动腺病毒复制的细胞型特异性启动子; 和(b)至少一个并入病毒主要晚期转录单位的报告基因。 在另一个实施方案中,腺病毒构建体包含(a)可操作地连接到E1基因的前列腺选择性前 - 盆地启动子; 和(b)可操作地连接到probasin启动子的前列腺特异性抗原增强子。

    COMPOSITIONS AND METHODS FOR RETARGETING VIRUS CONSTRUCTS
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR RETARGETING VIRUS CONSTRUCTS 有权
    用于重建病毒结构的组合物和方法

    公开(公告)号:US20130315870A1

    公开(公告)日:2013-11-28

    申请号:US13807359

    申请日:2011-06-29

    IPC分类号: C12N15/86 C12N15/10

    摘要: The present invention relates to the field of viral gene therapy. More specifically, A the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP, wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP inserted into the HI-loop of adenovirus fiber protein. In yet another embodiment, the present invention provides a method for optimizing adenoviral infection of target cells comprising the steps of (a) generating a peptide-display adenovirus library, wherein the displayed peptide is a peptide that specifically binds an antigen expressed on the surface of a target cell, and wherein the displayed peptide is flanked by random peptide sequences; and (b) screening the peptide-display adenovirus library against the target cells.

    摘要翻译: 本发明涉及病毒基因治疗领域。 更具体地,本发明提供了用于重新靶向病毒构建体的组合物和方法。 在一个实施方案中,本发明提供了包含编码肽序列MAE-X-PDP的核酸的腺病毒构建体,其中X是抗原靶向肽。 在更具体的实施方案中,腺病毒构建体包含编码插入到腺病毒纤维蛋白的HI环中的肽序列MAEWQPDTAHHWALTLPDP的核酸序列。 在另一个实施方案中,本发明提供了用于优化靶细胞的腺病毒感染的方法,包括以下步骤:(a)产生肽显示腺病毒文库,其中所显示的肽是特异性结合表达在 靶细胞,并且其中所显示的肽侧翼为随机肽序列; 和(b)筛选针对靶细胞的肽显示腺病毒文库。

    Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
    6.
    发明申请
    Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product 有权
    通过修饰e1a基因产物增强前列腺细胞中的腺病毒溶瘤活性

    公开(公告)号:US20060148073A1

    公开(公告)日:2006-07-06

    申请号:US10523899

    申请日:2003-08-08

    摘要: The present invention relates to compositions and methods for enhancing the oncolytic activity of replication-competent, target cell-specific adenovirus vectors by modification of the E1A gene product. The target cell-specific replication-competent adenovirus vectors comprise a chimera of an adenovirus gene essential for replication, preferably an early gene, and the Androgen receptor (or a portion thereof) under the transcriptional control of a cell type-specific transcriptional regulatory element (TRE). By providing for cell type-specific transcription through the use of one or more cell type-specific TREs, the adenovirus vectors effect prostate-specific cytotoxicity due to selective replication.

    摘要翻译: 本发明涉及通过修饰E1A基因产物增强复制能力的靶细胞特异性腺病毒载体的溶瘤活性的组合物和方法。 靶细胞特异性复制能力的腺病毒载体包含在细胞类型特异性转录调控元件的转录控制下对复制必需的腺病毒基因的嵌合体,优选早期基因和雄激素受体(或其部分) TRE)。 通过使用一种或多种细胞型特异性TRE提供细胞类型特异性转录,腺病毒载体由于选择性复制而影响前列腺特异性细胞毒性。

    Compositions and methods for treatment of cancer using tissue-specific oncolytic adenoviruses
    10.
    发明授权
    Compositions and methods for treatment of cancer using tissue-specific oncolytic adenoviruses 有权
    使用组织特异性溶瘤腺病毒治疗癌症的组合物和方法

    公开(公告)号:US08859287B2

    公开(公告)日:2014-10-14

    申请号:US13511878

    申请日:2010-12-02

    摘要: The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer.

    摘要翻译: 本发明包括使用编码shRNA的核酸序列来靶向针对细胞因子的RNA干扰,其中这种用途可以增强溶瘤性腺病毒复制。 可以通过重组事件将编码shRNA的核酸序列引入溶瘤腺病毒构建体,并且编码shRNA的核酸序列可以位于溶瘤腺病毒构建物的E1区域或纤维区域中。 特别地,溶瘤腺病毒构建体任选地包括用于在前列腺癌细胞中发挥特异性表达的前列腺特异性启动子或前列腺特异性增强子。 本发明的溶瘤腺病毒构建体可用于治疗癌症,特别是前列腺癌。